Page
Menu
  Sitemap

Welcome To Omaha Mediator

.
Robust humoral and cellular immune responses and low risk for reinfection at least eight months following asymptomatic to mild COVID-19.
Havervall S, Ng H, Falk AJ, Greilert-Norin N, Månberg A, Marking U, Laurén I, Gabrielsson L, Salomonsson AC, Aguilera K, Kihlgren M, Månsson M, Rosell A, Hellström C, Andersson E, Olofsson J, Skoglund L, Yousef J, Pin E, Lord M, Åberg M, Hedhammar M, Tegel H, Dönnes P, Phillipson M, Nilsson P, Klingström J, Mangsbo S, Hober S, Thålin C..
Discovery and evaluation of entry inhibitors for SARS-CoV-2 and its emerging variants.
Acharya A, Pandey K, Thurman M, Klug E, Trivedi J, Sharma K, Lorson CL, Singh K, Byrareddy SN..
.
.
Page
Menu